Skip to main content

Table 2 Treatment Response in Base-Case ICER Model

From: Monthly migraine days, tablet utilization, and quality of life associated with Rimegepant – post hoc results from an open label safety study (BHV3000–201)

Level of Migraine Pain at Time points, %

Rimegepant

Usual Care

Baseline (0 h), %

 None

0.0

0.0

 Mild

0.0

0.0

 Moderate

66.6

66.6

Severe

33.4

33.4

 2 h, %

 None

21.0

11.0

 Mild

33.0

24.0

 Moderate

30.6

43.3

 Severe

15.4

21.7

8 h, %

 None

71.8

53.5

 Mild

23.6

32.8

 Moderate

3.1

9.1

 Severe

1.6

4.6

24 h, %

 None

76.4

68.3

 Mild

19.5

21.5

 Moderate

2.7

6.8

 Severe

1.4

3.4

48 h

 None

82.4

77.4

 Mild

12.9

13.6

 Moderate

3.1

5.9

 Severe

1.6

3.0

Resulting hours of pain per 48-h migraine event

Rimegepant

Usual Care

 None

32.5

27.8

 Mild

8.9

10.0

 Moderate

4.4

6.8

 Severe

2.2

3.4

  1. Source: Atlas et al. 202033